Guardant Health Lands $100,000,000 Series D Funding Round
Feed Type
Link http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=014db92e-45f6-423f-9d9f-cc53650f67f0
Date 1/7/2016
Company Name Guardant Health
Mailing Address 505 Penobscot Dr. Redwood City, CA 94063 USA
Company Description Guardant360 is the only biopsy-free tumor sequencing test that tracks tumor genomics in real-time and identifies associated treatment options.
Proceeds Purposes The funding will help Guardant Health build on its leading technological and commercial positions to further expand the adoption of Guardant360, the world’s first comprehensive, non-invasive genomic sequencing test for cancer. The investment will go toward Guardant Health’s Digital Sequencing platform to power additional breakthrough products geared toward addressing the full spectrum of the cancer-care continuum.